|

Prevalence of Adrenal Insufficiency and Associated Factors in Rheumatoid Arthritis Patients Using Low-dose Corticosteroids.

RECRUITINGSponsored by Bursa Yuksek Ihtisas Training and Research Hospital
Actively Recruiting
SponsorBursa Yuksek Ihtisas Training and Research Hospital
Started2026-07-31
Est. completion2027-07-30
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted

Summary

This study aims to investigate the prevalence of adrenal insufficiency in rheumatoid arthritis (RA) patients receiving low-dose corticosteroid therapy and to identify the factors influencing adrenal insufficiency. To this end, the researchers plan to conduct a study comparing the prevalence of adrenal insufficiency and associated factors among RA patients-who are currently receiving low-dose corticosteroid therapy during outpatient follow-up and have consented to participate-by categorizing them into three groups based on the duration of treatment: short (3 weeks-3 months), medium (3-12 months), and long (\>12 months).

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Participants diagnosed with rheumatoid arthritis according to the 2010 ACR/EULAR criteria.
* Participants who have been undergoing corticosteroid treatment for at least 3 weeks.
* Participants in remission or with low disease activity (DAS28-CRP ≤3.2).

Exclusion Criteria:

* Patients with primary adrenal insufficiency.
* Participants who have received pulse steroid therapy within the last 6 months.
* Pregnancy and lactation.
* Hypopituitarism
* Uncontrolled diabetes mellitus
* Comorbidities; ≥NYHA Class 3 heart failure, Stage 3 chronic kidney failure, ≥Child-Pugh Class B liver cirrhosis

Conditions4

Adrenal InsufficiencyArthritisCorticosteroids Adverse ReactionReumatoid Arthritis

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.